Product Images Donepezil Hydrochloride

This is a chart displaying the results of a study comparing different doses of a medication called Donepes in treating patients with ADAS-20g. The chart shows the change in ADAS-20g scores after 24 weeks of treatment with a placebo or different doses of Donepes. The percentage of patients who completed the study is also indicated for each treatment group.*

The text seems to be legible and it describes a figure showing the time-course of the change from baseline in ADAS-cog score for patients completing a 15-week clinical study. The figure shows the clinical improvement of patients with Donepest HeI 10mg/day compared to the placebo group. The data is presented in a graph format with x-axis indicating the weeks of drug treatment and y-axis indicating the change from baseline in ADAS-cog score.*

The text provides a frequency distribution graph of CIBIC-plus scores at week 12. The graph displays the percentage of patients who experienced different levels of improvement or worsening of their condition based on their CIBIC-plus rating, which was evaluated under three different treatment plans: placebo, 5mg/day, and 10mg/day. The ratings include "markedly improved," "moderately improved," "minimally improved," "no change," "minimally worse," "moderately worse," and "markedly worse."*

Figure 7 illustrates the time course of change from baseline in SIB score for patients completing 6 months of treatment. The mean change from baseline is shown as 18 (=SE) for patients taking donepezil HCI 10 mg/day, represented by the symbol e, and as 8 for those taking placebo, represented by the symbol o. There is clinical improvement observed after 3 months of drug treatment.*

The figure labeled "Figure 9" shows the time course of change from baseline in ADCS-ADL-Severe Score for patients who completed 6 months of treatment. The x-axis represents the duration of drug treatment in months, while the y-axis represents the degree of clinical improvement in ADCS-ADL-Severe Score. The treatment used was Donepezil HCI 10 mg/day. No further information is available for evaluation.*

description: NDC 0781-5276-64 is a drug named Donepezil Hydrochloride that is available in the form of orally disintegrating tablets by Beonly. The package contains 30 tablets arranged in 3 x 10 unit-dose. The pharmacist should dispense the medicine with the patient information sheet. A warning for phenylketonurics is displayed on the package, that these tablets contain 4,72 mg Phenylalanine per tablet. Additionally, it is mentioned not to use the drug if blisters are broken, missing, or torn. The drug is manufactured by SANDOZ.*

product used for the treatment of dementia and Alzheimer's disease. This specific product is an orally disintegrating tablet form of Donepezil Hydrochloride, packaged in 30 tablets (3 x 10 unit-dose) by the company Beonly. The package includes a warning not to use the tablets if the blister packaging is torn, broken, or missing. Additionally, the product contains Phenylalanine and is not recommended for individuals with Phenylketonuria.*